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Background: Epstein-Barr virus (EBV) is considered to be closely associated with nasopharyngeal carcinoma (NPC),
in which EBV-encoded latent membrane protein 1 (LMP1) was found to have an oncogenic role. However, the results
published on the LMP1 polymorphism are inconsistent. In the present study, we performed a meta-analysis to
determine the frequency of the associations and a more precise association between NPC and EBV LMP1 gene
variants (30-bp deletion (del)/XhoI-loss).
Methods: Eligible articles met the inclusion/exclusion criteria and were identified in the following electronic
databases: PubMed, ScienceDirect, and SciELO. Consequently, the data of interest were extracted and plotted in
a table to calculate the frequency and odds ratio (OR) of the outcomes of interest (30-bp del-LMP1/XhoI-loss) in
patients with NPC. Study quality (Newcastle-Ottawa Scale (NOS)), publication bias, and heterogeneity were assessed.
Results: Thirty-one observational studies were included with a total of 2,846 individuals (NPC, n = 1,855; control, n = 991).
The risk of bias in relation to study quality evaluated by NOS was considered low. The pooled estimate of the
frequency of 30-bp del-LMP1 and XhoI-loss in patients with NPC was 77% (95% confidence interval (CI): 72 to
82) and 82% (95% CI: 71 to 92), respectively. There was an association between 30-bp del-LMP1 and NPC
susceptibility (OR = 2.86, 95% CI: 1.35 to 6.07, P = 0.00). Similarly, there was an association between XhoI-loss
and NPC (OR = 8.5, 95% CI: 1.7 to 41, P = 0.00). However, when we analyze the co-existence of the 30-bp del-LMP1 and
XhoI-loss in patients with NPC, there was no association (OR = 1.09, 95% CI: 0.06 to 18.79, P = 0.002).
Conclusions: Our results suggest an association between the 30-bp del-LMP1 and XhoI-loss with NPC susceptibility.
However, our data should be interpreted with caution because the sample size was small, and there was heterogeneity
between the studies. Thus, future studies are needed with adjusted estimates to simultaneously evaluate multiple factors
involved in the development of NPC.
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Nasopharyngeal carcinoma (NPC) is an aggressive tumor
associated with Epstein-Barr virus (EBV) that initially
affects the layer of epithelial cells in the nasopharynx
and preferably arises in the Rosenmüller’s fossa [1,2].
NPC is also defined as a peculiar type of head and neck
cancer due to its clinical status, etiology, pathology,
epidemiology, and manner of response to treatment
[3,4]. In view of these factors, EBV and NPC have very
distinct epidemiological and clinical patterns, given
that EBV is ubiquitous and causes a latent infection in
95% of the world population, with the majority of
these infections being benign [5]. However, the world-
wide incidence of NPC is considered rare, and affected
individuals for many years had a poor prognosis that
reflected in a reduced survival rate, but actually the
survival of NPC patients is relatively high under the
current treatment protocol and the introduction of
intensity-modulated radiotherapy (IMRT) [6].
Although NPC endemicity is rare in most parts of the
world [7], there is a striking geographic and ethnic
distribution of cases characterized by existing areas of
high endemicity (Southeast Asia), intermediate endem-
icity (Eastern Mediterranean and North Africa), and low
endemicity (Americas). According to data provided by
GLOBOCAN 2012 [8], in the same period in the world,
the total number of NPC was 86,691 cases (age-stan-
dardized rate (ASR), 1.2/100,000)), while the number of
deaths was 50,831 (ASR = 0.7/100,000). Among these
cases, China was the country that contributed the most
to these indices because it had the highest total number
(33,198, ASR = 1.9/100,000) and deaths (20,404, ASR =
1.2/100,000) by NPC, followed by Indonesia (13,084
cases, ASR = 5.6/100,000 and 7,391 deaths with ASR =
3.3/100,000) and Vietnam (4,931 cases, ASR = 5.4/
100,000 and 2,885 deaths with ASR = 3.3/100,000).
EBV infects the mucosal epithelium and B cells and
consequently establishes a latent infection, and aberrant
infection by EBV can to cause the appearance of tumors
in these locations of replication [9]. Hence, infected cells
may present physiological changes that result from the
expression of latent genes, including mainly EB-encoded
early RNAs (EBER), EBV nuclear antigens (EBNA1/2/3a,b,c)
and latent membrane protein 1 or 2 (LMP1/2) [10].
The first protein from EBV to have its oncogenic proper-
ties empirically demonstrated was LMP1 [11], which is
expressed on the cell surface, where it spontaneously aggre-
gates to form a constitutively activated receptor, acting as a
member of the tumor necrosis factor receptor (TNF-R)
family and allowing LMP1 to exert an influence on the cell
through interactions with different cellular molecules in-
volved in an intracellular signaling cascade [12-15]. Conse-
quently, a number of studies have shown the involvement
of LMP1 in the pathogenesis of NPC [16,17], whichinvolves the following factors: 1) an inhibition of apoptosis
in the infected cells by the upregulation of Bcl-2 and A-20
genes [13,15,18]; 2) a modulation of the morphology and
motility of epithelial cells [19]; 3) a downregulation of
several suppressors for metastases [20]; 4) a promotion of
angiogenesis [21]; and 5) an induction of the expression of
proinflammatory cytokines, among other mechanisms
[22,23]. LMP1 is an integral membrane protein that can be
divided into three domains: 1) a short cytoplasmic N-
terminal tail (amino acids 1 to 23); 2) six transmembrane
alpha-helical of hydrophobic nature (amino acids 24 to
186); and 3) a long cytoplasmic C-terminal tail (amino acids
187 to 386), with this region having the highest LMP1 sig-
naling activity. Therefore, the long cytoplasmic C-terminal
tail has three distinct functional domains: C-terminal acti-
vation regions 1, 2, and 3 (CTAR1/2/3) [24,25].
The LMP1 gene has been shown to have polymorphisms,
among which the occurrence of a 30-bp deletion is prom-
inent, as compared with the prototype B95-8 LMP1, and
occurs near the end of the cytoplasmic C-terminal tail and
close to the functional domain CTAR2. This feature
deletion has been studied, and it has been established
that the 30-bp deletion results in an increased oncogenic
activity of infected cells and results in a more aggressive
phenotype of EBV-associated tumors [26,27]. In addition,
another mutation observed in the LMP1 gene, albeit a
point mutation, occurs at nucleotide position G169425T,
resulting in the loss of a restriction site known as XhoI,
which is present in the cytoplasmic N-terminal tail. Thus,
the XhoI polymorphism has been commonly found in
samples from patients with NPC but is absent in samples
from healthy individuals [28,29]. However, in general, the
results of the studies are ambiguous regarding the associ-
ation of these variants in the EBV LMP1 gene with the risk
of developing NPC. In this sense, this meta-analysis was
performed to solve the problem of inadequate statistical
power and of the controversial and ambiguous results.
Methods
We followed the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) protocol, which
provides rules and guidelines for systematic reviews and
meta-analysis [30]. The PRISMA checklist is shown in
Additional file 1. In addition, we prospectively recorded
the study protocol in PROSPERO with the registration
number CRD42014013496, available on the website
http://www.crd.york.ac.uk/PROSPERO/display_record.
asp?ID=CRD42014013496#.VBg8HoctBdg.
The identification and eligibility of relevant studies
To address our study hypothesis, the following electronic
databases were searched: PubMed, ScienceDirect, and
SciELO. The selection period lasted until the beginning of
September 2014, and the language of the studies to be
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Portuguese. Therefore, in these three electronic data-
bases, the following keywords related to our research
topic were added: Epstein-Barr virus OR EBV OR virus
AND cancer OR tumor OR neoplasia OR nasopharyngeal
carcinoma AND LMP1 30-bp deletion OR LMP1 variant
OR BNLF1 AND XhoI polymorphism OR XhoI variants.
We also adopted another strategy to search the data to re-
duce possible selection bias, which was the recovery of all
references of ‘pre-selected’ studies to retrieve articles of
interest available only in other electronic databases. Finally,
the selection criteria were as follows: 1) cohort or case–
control studies that analyzed the 30-bp deletion and/or
XhoI-loss present in the EBV LMP1 gene of patients with
NPC; and 2) studies that showed the variables of interest
as previously stated were selected regardless of the place of
origin of the search, age, and sex as well as the histological
type of NPC presented by these individuals. The exclusion
criteria included the following: 1) review studies; 2) analysis
only of other cancers ‘non-NPC’; 3) duplicated previous
publications; and 4) studies that did not disclose the vari-
ables of interest as the frequency of the 30-bp deletion or
the XhoI polymorphism in the EBV LMP1 gene separately
for patients with NPC.
Data extraction and quality assessment
The researchers independently reviewed and extracted
information from the eligible studies according to the
inclusion and exclusion criteria previously highlighted.
Thus, the following data were extracted: the identifica-
tion and design of the study, the year of publication, the
number of subjects and controls who had NPC, the
types of controls (healthy or pathological), the study site,
the age and sex of the research subjects, the frequency of
the outcomes of interest as the 30-bp deletion or XhoI-loss
from the EBV LMP1 gene. To assess the methodological
quality of observational studies was used Newcastle-
Ottawa Scale (NOS) in which a study was judged on three
categories: selection (four items, one star each), compar-
ability (one item, up to two stars), and exposure/outcome
(three items, one star each). A ‘star’ presents a ‘high-quality’
choice of individual study. The full score was 10 stars, and
the high-quality study was defined as a study with ≥6
awarded stars [31].
Statistical analysis
The dichotomous data of the case–control studies were
extracted and plotted in a 2 × 2 table to give the individual
and combined odds ratios (OR). For the cohort studies,
which have binary data, the variables were extracted to
calculate an estimate of the frequency of the outcomes of
interest, and a confidence interval (CI) of 95% was used
whenever possible. The I2 index was used to evaluate the
existence of heterogeneity between the studies; for caseswhere there were significant differences in terms of
heterogeneity (I2 = 75% to 100%, P < 0.05) [32], the
random-effect model was used for the individual and
combined analysis of the data. We conducted a sensitivity
analysis to test the effect of the individual influence of
each study on the overall estimate, and a subgroup ana-
lysis was also performed to reduce the existence of hetero-
geneity. Furthermore, we evaluated the existence of
publication bias by Begg’s funnel plot [33] and by Egger’s
test [34]. The funnel plot for the case–control studies was
developed from the standard error of the log (OR) for
each analysis against the log (OR), whereas the funnel plot
of the cohort studies was plotted from the standard error
log (percent) against the log (percent). For all of the proce-
dures of the meta-analysis, STATA IC/64 version 13.1
software (Stata Corporation, College Station, Texas, USA)
was used.
Results
Initially, during our search for articles in the electronic
databases, 1,280 reference studies were found (see
Additional file 2). Subsequently, due to the selection of
the inclusion and exclusion criteria, there was a refine-
ment to 75 reference studies (see Additional file 3).
Finally, 31 eligible studies remained, which constituted
our database for conducting the present meta-analysis
(Table 1) [29,35-64]. A total of 2,846 subjects were in-
cluded in these studies, among which 1,855 and 991 in-
dividuals were placed in NPC and control groups,
respectively. Regarding the sex of the individuals, there was
a male predominance with a male/female ratio of 2.73
[39-42,46,49,53,54,57]. The age of the participants ranged
from 8 to 87 years; however, the predominant age was ap-
proximately 50 years old [35,40,41,43,46,49,53-55]. Most of
the participants came from Asia (approximately 71%)
[29,35,36,38-41,43,46,47,49-51,53,55,57-59,61-64], followed
by Europe (26%) [29,36,37,48,54,56,62,63], North Africa
(19%) [42,44,52,56,60,62], and America (13%) [45,54,62,63].
Similarly, the samples were from at least 12 countries, con-
sisting mainly of China, Taiwan, Russia, Malaysia, Tunisia,
Indonesia, Thailand, Serbia, and Morocco. With regard to
case–control studies, all had an NOS score of 7. In the co-
hort studies, 5 (42%) were of high quality (NOS score ≥6),
with an average NOS score of 5 (see Additional file 4). Thus,
the risk of bias in relation to study quality evaluated by
NOS was considered low with a score ranging from 4 to 7.
A meta-analysis to estimate the frequency of the 30-bp
deletion and XhoI-loss (LMP1 EBV) in samples from NPC
patients
The estimated frequencies of the EBV LMP1 variants in
the samples from the NPC patients were determined
and are shown in Figure 1. Thus, the estimated pooled
frequency of 30-bp del-LMP1 was 77% (95% CI: 72 to
Table 1 The characteristics of the studies included in the meta-analysis













Senyuta et al. 2014 [35] Russia Case–control 4 18 Biopsy 15 PBMC HD
Gurtsevitch et al. 2013 [36] Russia Case–control 3 18 Biopsy 13 PBMC Non-NPC
Banko et al. 2012 [37] Serbia Case–control 1 15 Biopsy 30 PBMC IM
Li et al. 2009 [38] China Case–control 43 7 Biopsy 56 PBMC HD
See et al. 2008 [39] Malaysia Case–control 19 15 Biopsy 34 5 Biopsy 8 Biopsy Non-NPC
Tang et al. 2008 [40] China Cohort 18 3 Biopsy 21 0 Biopsy
Tiwawech et al. 2008 [41] Thailand Case–control 44 31 PBL 44 PBMC Non-NPC/HD
Ayadi et al. 2007 [42] Tunisia Cohort 41 6 Biopsy 0 47 Biopsy
Chang et al. 2006 [43] Taiwan Cohort 446 88 Biopsy
Dardari et al. 2006 [44] Morocco Case–control 51 10 Biopsy 17 PBMC HD
Chabay et al. 2004 [45] Argentina Case–control 3 1 Biopsy 15 Biopsy/
PBMC
Non-NPC
Min et al. 2004 [46] China Case–control 87 12 Biopsy 46 PBMC HD
Nurhantari et al. 2003 [47] Indonesia Cohort 22 33 Biopsy
Plaza et al. 2003 [48] Spain Case–control 18 9 Biopsy 40 - EBV-RC
Tan et al. 2003 [49] Malaysia Case–control 25 0 Biopsy 25 2 Biopsy 12 Biopsy
Zhang et al. 2002 [50] China Case–control 36 7 Biopsy 36 TW HD
Hahn et al. 2001 [51] Russia Case–control 0 7 Biopsy 10 PBMC HD
Henry et al. 2001 [52] Tunisia Cohort 3 3 Biopsy 0 6 Biopsy
Kuo et al. 2001 [53] Taiwan Cohort 2 0 Biopsy
D’Addario et al. 2000 [54] Canada Cohort 9 14 Biopsy
Cheung et al. 1998 [55] China Cohort 34 3 Biopsy
Grunewald et al. 1998 [56] Multicenter Case–control 46 18 Biopsy 45 PBMC HD
Sung et al. 1998 [57] China Cohort 30 12 Biopsy 22 6 Biopsy
Cheung et al. 1996 [58] China Case–control 69 5 Biopsy 5 0 Biopsy 11 Biopsy Non-NPC
Khanim et al. 1996 [29] Multicenter Case–control 24 4 Biopsy 19 9 Biopsy 14 Biopsy/
PBMC
Non-NPC
Chang et al. 1995 [59] Taiwan Case–control 48 0 Biopsy 25 Biopsy/TW HD
Bouzid et al. 1994 [60] North Africa Cohort 1 12 Biopsy
Jeng et al. 1994 [61] Taiwan Case–control 25 7 Biopsy 79 Non-NPC
Miller et al. 1994 [62] Multicenter Cohort 9 4 Biopsy
Abdel-Hamid et al. 1992 [63] Multicenter Case–control 33 18 Biopsy 19 - Non-NPC
Hu et al. 1991 [64] Multicenter Cohort 38 18 Biopsy
Abbreviations: PBMC = peripheral blood mononuclear cell; PBL = peripheral blood lymphocyte; HD = healthy donors; IM = infective mononucleosis; TW = throat
washing samples; NPC = nasopharyngeal carcinoma.
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trols and pathological samples, the estimated pooled
frequency of 30-bp del-LMP1 was 46% (95% CI: 33 to
58, P = 0.00) and 39% (95% CI: 31 to 47, P = 0.49)
(Additional file 5), respectively, that is, both of the
control group frequencies were lower than those in the
samples from the NPC patients.
For the XhoI-loss variable, the estimated pooled fre-
quency was 82% (95% CI: 71 to 92, P = 0.00) in the NPCpatients (see Figure 1). For the healthy and pathologic
groups, the pooled rate was 62% (95% CI: 33 to 91, P =
0.002) and 76% (95% CI: 68 to 84, P = 0.3), respectively
(Additional file 5).
The estimated pooled frequency was 79% (95% CI: 73
to 85, P = 0.00) for 30-bp del-LMP1 in the NPC patients
found in Asia, which was the largest among the regions
studied. The second highest frequency was observed in
America, with a pooled frequency of 64% (95% CI: 35 to
Figure 1 Forest plot of the frequency of the occurrence of the two outcomes of interest in the patients with NPC. The confidence interval (CI)
was 95%, and the diamond represents the pooled estimate. ID = identification of study.
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was 59% (95% CI: 45 to 73, P = 0.00), which was observed
in Europe and North Africa. Similarly, the pooled fre-
quency of XhoI-loss in individuals with NPC was higher
for studies conducted in Asia (92%, 95% CI: 87 to 98,
P = 0.00), followed by America (29%, 95% CI: 0 to 100)
and by the regions from Europe and North Africa (9%,
95% CI: 0 to 44) (Additional file 6).
A meta-analysis of the association between the 30-bp
del-LMP1 and XhoI-loss with NPC susceptibility
The OR, known as an association test, was calculated to
assess the relationship between the LMP1 variants and
NPC. Thus, there was a significant association between
the 30-bp del-LMP1/XhoI-loss and NPC susceptibility
(30-bp del-LMP1: OR = 2.86, 95% CI = 1.35 to 6.07, P =
0.00; XhoI-loss: OR = 8.5, 95% CI = 1.7 to 41, P = 0.00)
(Figure 2). However, when we analyzed the association
of the occurrence of the simultaneous outcome, that
is, the co-existence of the 30-bp del-LMP1 and XhoI-
loss with the susceptibility to NPC, there was not a signifi-
cant association (OR = 1.09, 95% CI: 0.06 to 18.79, P =
0.002) (data not shown). However, there was significantheterogeneity, and due to this factor, the studies were ana-
lyzed in subgroups.
The histological subsets of the NPC and LMP1 EBV variants
According to the World Health Organization (WHO),
NPC can be classified into three types according to the
degree of histopathological differentiation, which include
type I (keratinizing squamous cells carcinoma), type IIa
(non-keratinizing, previously classified as type II), and type
IIb (undifferentiated carcinoma, previously classified as type
III) [65]. Therefore, when the selected studies reported this
information, they were divided according to the histopatho-
logical classification to assess the association between the
types of NPC and the EBV LMP1 variants. Thus, a sig-
nificant association was found between the occurrence
of 30-bp del-LMP1 with type III NPC (OR = 2.6, 95%
CI: 1.12 to 6.03, P = 0.006) and also with type I/II NPC
(OR = 2.65, 95% CI: 1.45 to 4.85, P = 0.7). Similarly,
there was a significant association between type III NPC
and XhoI-loss (OR = 65, 95% CI: 1.8 to 2,369, P = 0.1);
likewise there was an association for types I/II NPC and
XhoI-loss (OR = 13.67, 95% CI: 3.12 to 60, P = 0.3)
(Additional file 7).
Figure 2 Forest plot of the OR for the 30-bp del-LMP1 and XhoI-loss in NPC. The diamond represents the pooled OR and its 95% confidence
intervals (CIs). ID = identification of study.
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susceptibility to NPC by study region
A significant association between 30-bp del-LMP1 and
the susceptibility to NPC was found in the studies con-
ducted in Asia (OR = 3.47, 95% CI: 1.36 to 8.86, P =
0.00), while for the studies conducted in Europe and
North Africa, there was no association (OR = 1.01, 95%
CI: 0.3 to 3.4, P = 0.00) (Figure 3A). Similarly, there was
a higher association between XhoI-loss and NPC sus-
ceptibility for studies conducted in Asia (OR = 12.35,
95% CI: 3.98 to 38, P = 0.27). For the studies conducted
in Europe and North Africa, there was no association
between XhoI-loss and NPC susceptibility because the
pooled OR was 0.12 (95% CI: 0.01 to 1.17, P = 0.5)
(Figure 3B).Sensitivity analysis and publication bias
The studies that presented results considered discordant
were temporarily removed to assess their individual in-
fluences on the pooled ORs. The individual removal did
not significantly affect the pooled OR. However, due to
the large variation of the ORs between 30-bp del-LMP1
and the susceptibility to NPC found in the studies of Li
et al. [38] and Tan et al. [49], the ORs were removed,
and the pooled OR was reduced by 31%, reaching 2.86
(95% CI: 1.35 to 6.07) to 1.96 (95% CI: 1.05 to 3.66, P =
0.001). Similarly for XhoI-loss, the See et al. [39] and
Tan et al. [49] studies exhibited an OR very different
from the other studies, and when both were removed,
the pooled OR was reduced by 8.5 and equaled 3.69
(95% CI: 0.75 to 18, P = 0.005). However, removing these
Figure 3 Forest plot of the odds ratio (OR) in relation to the origin from the studies for the outcome of the 30-bp del-LMP1 (A) and XhoI-loss (B)
in patients with NPC. CI = confidence interval; ID = identification of study.
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found. Therefore, the reduction of heterogeneity ob-
served in the studies that analyzed 30-bp del-LMP1 oc-
curred when the following studies were removed:
Senyuta et al. [35], Gurtsevitch et al. [36], Banko et al.
[37], Li et al. [38], and Hahn et al. [51]. In this case, the
heterogeneity was reduced to 48% (P = 0.036) with an
OR of 3.51 (95% CI: 2 to 6) (data not shown).
For the studies that analyzed XhoI-loss, only the study
conducted by Khanim et al. [29] was found to cause het-
erogeneity, and when it was removed, the heterogeneity
decreased to 19% (P = 0.28) with a pooled OR of 16.83
(95% CI: 6 to 43).
For the analysis of the publication bias, a funnel plot was
used, and because it was symmetrical, it indicated that the
existence of a selection bias was unlikely (Additional file 8).
Additionally, by Egger’s test, there was also no sign of the
occurrence of a selection bias for the studies included in
the estimate of the OR and for the studies that analyzedthe outcome of 30-bp del-LMP1 (coefficient −1.22,
95% CI: −4 to 1.64, P value 0.36) or XhoI-loss (coeffi-
cient −8.2, 95% CI: −248 to 231, P value 0.7) in the bi-
opsies from the NPC patients. Additionally, regarding the
calculation of the frequency, there was no sign of publica-
tion bias by the funnel plot and by Egger’s test (30-bp del-
LMP1, coefficient −0.9, 95% CI: −2 to 0.2, P value 0.1;
XhoI, coefficient 0.2, 95% CI: −2.8 to 3.2, P value 0.9).
Discussion
This meta-analysis provided evidence that both the 30-
bp deletion and XhoI-loss (EBV LMP1 gene) were more
frequently found in the samples from patients with NPC
than in the control groups. In this case, 30-bp del-LMP1
was 1.5 times higher in the NPC patients than in the
control group. While the outcome of XhoI-loss was only
1.15 times higher in the NPC patients than in the con-
trol group, the simultaneous occurrence of the outcomes
of interest (the co-existence of the 30-bp del-LMP1 and
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ation (OR = 1.9, 95% CI: 0.06 to 18.79), although this re-
sult has been found by a few studies. This result shows
that LMP1 variants occur with a considerable frequency
in healthy subjects; therefore, there are many other non-
viral factors involved in the etiopathogenesis of NPC.
Thus, it is known that the development of NPC is multi-
factorial, involving the existence of a genetic predispos-
ition of the individual, along with environmental factors
[66]. However, one of the factors that has been most
often correlated with the risk of NPC is the viral factor.
Because the etiology of NPC is complex, other meta-
analyses have emerged to analyze the involvement of
various factors in the susceptibility to NPC. In this sense,
Xue et al. [67] conducted a meta-analysis of cohort and
case–control studies to establish the relationship
between smoking and the risk of NPC. This analysis
showed that individuals who smoked always had a 60%
greater probability of risk for NPC compared to that of
individuals who have never smoked. Regarding genetic
predisposition, studies have found an association be-
tween glutathione S-transferase M1 (GSTM1) and gluta-
thione S-transferase T1 (GSTT1) with an increased risk
for the development of NPC [67,68]. Also, the role of
human leukocyte antigen (HLA) in the emergence of
NPC has been examined, and some specific haplotypes
and/or alleles from the HLA region have been associated
with NPC [69-71]. For this reason, studies have found a
high prevalence of HLA allele patterns found in endemic
NPC regions, for example, HLA-A2 and HLA-Bw46
[72,73], which were associated with an increased risk for
the development of NPC. These results have shown that
many genes may contribute to an increased susceptibility
to NPC, and some interesting studies show that there is
a pattern of distribution of the HLA haplotypes and/or
alleles that vary in different geographical areas character-
ized by differences in the prevalence of NPC [72-75].
LMP1 is considered an oncogenic product from EBV,
and although its expression has been positively corre-
lated with metastasis in NPC [76], its etiopathogenesis
remains poorly understood. In this context, authors have
postulated that variants of LMP1 exist with greater
tumorigenic potential, such as the specific 30-bp deletion
at the C-terminal region and the loss of the restriction site
at the N-terminus (XhoI), which were our target outcomes
of interest. Consequently, our meta-analysis has found that
there was a positive association, but we postulated that at
this moment, this outcome alone does not explain the risk
of the emergence and development of NPC because these
LMP1 variants were also found with a considerable fre-
quency in the control groups. Similarly, these LMP1 vari-
ants were found in other cancers, such as Burkitt’s
lymphoma [77], gastric carcinoma [78], and Hodgkin’s
lymphoma [79,80], and also in the Japanese population[81]. With this background, the two LMP1 variants cannot
be considered specific markers of NPC but could be con-
sidered the predominant variants in this type of cancer.
One factor that always draws attention in NPC is its
remarkable geographical distribution because, while
NPC is rare in most of the world, for the Southeast
Asian region, especially in the South China region, this
type of cancer is endemic. For example, the incidence of
NPC in some provinces of Southern China is up to 30
times higher than in the rest of the world [82]. Thus, the
question inevitably arises: what are the factors that ex-
plain the higher incidence of NPC in these endemic re-
gions? Initially, the answer was related to an increased
susceptibility of the people of these regions with the 30-
bp del-LMP1 variant, as this is a variant commonly
found in NPC biopsies. However, Zhang et al. [50] found
similar levels of this LMP1 polymorphism among sam-
ples from endemic and non-endemic regions in South
and North China, respectively. Therefore, the LMP1
variant failed to explain the high incidence of NPC in
China, showing that there are other complex factors.
Although these regions are composed of a very similar
ethnic group, most likely, there are some genetic differ-
ences among this population. Accordingly, Wang et al.
[83] found a higher frequency of HLA-A (*)30 in healthy
individuals from the North China region, which has been
associated with NPC resistance. Additionally, Ren et al.
[84] found that the risk of developing NPC increases with
a family history of the disease, meaning that individuals in
South China who have a greater family history and inci-
dence of NPC consequently have a greater susceptibility
to NPC.
As previously mentioned, although EBV is associated
with NPC, it most likely is not the only factor that would
justify the high incidence of NPC in some parts of the
world. A set of factors could contribute to the emergence
of NPC, such as the type of diet, especially considering that
multiple dietary factors, such as a high consumption of
salted fish and eggs have been associated with the risk of
NPC [85]. In addition, several authors have consistently
found an associated risk between NPC and individuals
who often feed on salt-preserved fish. These data were ob-
tained from regions endemic for NPC, where this type of
food is traditional for the people who live in these places
[86,87].
This is the first meta-analysis that evaluated an associ-
ation between the 30-bp deletion and XhoI-loss (EBV
LMP1 gene) on the risk of NPC. Our results suggest an
association between the outcomes of interest. However,
we recognize that there were some limitations in our
study. First, there was significant heterogeneity in the re-
sults; thus, a sensitivity analysis and subgroups showed
that the types of controls and histologic types from NPC
caused heterogeneity, but we did cannot determine if
da Costa et al. Systematic Reviews  (2015) 4:46 Page 9 of 11other variables such as the sample size or the origin of the
studies caused the heterogeneity. Second, the loss of the
original data from the reviewed studies limited our evalu-
ation of other potential interactions, such as survival ana-
lysis and the stage of NPC associated with the LMP1
variants. Third, the number of studies included in the ana-
lysis was high, but the sample sizes included in the studies
were modest. This factor may reduce the statistical power
of the association between the outcome of interest and the
risk of cancer. Fourth, articles in the Chinese language were
not included; consequently, there is a possibility of a selec-
tion bias, even with the funnel plot and Egger’s test indicat-
ing no significant publication bias. Finally, our results of the
ORs are based on unadjusted estimates, which may suffer
from a confounding bias; therefore, a more precise analysis
is required and must be conducted and adjusted for other
factors jointly, such as cancer stage, age, sex, and genetic
and environmental factors involved.
Conclusions
Our results suggest an association between the 30-bp del-
LMP1 and XhoI-loss with NPC susceptibility. However,
our data should be interpreted with caution because the
sample size was small, and there was heterogeneity be-
tween the studies. For sensitivity analysis, individual
removal did not significantly affect heterogeneity and the
pooled ORs. In summary, further studies with a larger
number of individuals will be required to measure the
overall joint association of the various factors that might be
involved in the triggering of NPC.
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